



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
ASSISTANT SECRETARY OF COMMERCE AND
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

7/13/07

Patent No : 6,706,744 B2
Application No: 09/996,023
Issued : March 16, 2004
Inventor : Madsen, et al.
Title : GLUCAGON ANTAGONISTS/INVERSE
AGONISTS

Re: Request for Certificate of Correction

Consideration has been given your request for the issuance of a certificate of correction, for the above-identified patent under the provision of Rule 1.322 or 1.323.

Respecting the alleged errors, the changes to Column 74, lines 41 & 45; Column 78, line 30; and the deletion of Column 82, line 28 through Column 90, line 30 would change the meaning of the claims. Therefore, no correction(s) is in order here under United States Codes (U.S.C.) 254 or 255 the Code of Federal Regulation (C.F.R.) R1.322 or R1.323.

In view of the foregoing, your request in this matter is hereby denied.

A certificate of correction will be issued to correct the errors noted in your request.

Further correspondence concerning this matter should be filed and directed to Decisions and Certificates of Correction Branch. Any response must be filed within a four week period.

Valerie Jackson
Newman Cecelia
Decisions & Certificates
of Correction Branch
(703) 308-9390 ext. 114

Reza Green, Esq.,
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540

vj/CBN